Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 126

1.

Analogue synthesis reveals decoupling of antibiofilm and β-lactam potentiation activities of a lead 2-aminoimidazole adjuvant against Mycobacterium smegmatis.

Martin SE, Nguyen CM, Basaraba RJ, Melander C.

Chem Biol Drug Des. 2018 Aug;92(2):1403-1408. doi: 10.1111/cbdd.13208. Epub 2018 May 12.

PMID:
29663670
2.

Topical therapy for refractory rhinosinusitis caused by methicillin-resistant Staphylococcus aureus: First report in a prospective series.

Shikani AH, Khoueir N, Jabra-Rizk MA, Shikani HJ, Basaraba RJ, Leid JG.

Auris Nasus Larynx. 2018 Oct;45(5):994-999. doi: 10.1016/j.anl.2018.01.009. Epub 2018 Feb 6.

PMID:
29426723
3.

2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeability.

Jeon AB, Obregón-Henao A, Ackart DF, Podell BK, Belardinelli JM, Jackson M, Nguyen TV, Blackledge MS, Melander RJ, Melander C, Johnson BK, Abramovitch RB, Basaraba RJ.

PLoS One. 2017 Jul 27;12(7):e0180925. doi: 10.1371/journal.pone.0180925. eCollection 2017.

4.

Pathology of Tuberculosis: How the Pathology of Human Tuberculosis Informs and Directs Animal Models.

Basaraba RJ, Hunter RL.

Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0029-2016. Review.

PMID:
28597826
5.

Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions.

Basaraba RJ, Ojha AK.

Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0024-2016. Review.

PMID:
28597824
6.

Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms.

Ronacher K, van Crevel R, Critchley JA, Bremer AA, Schlesinger LS, Kapur A, Basaraba R, Kornfeld H, Restrepo BI.

Chest. 2017 Jul;152(1):174-180. doi: 10.1016/j.chest.2017.02.032. Epub 2017 Apr 20. Review.

7.

Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 1: Epidemiology and Clinical Management.

Critchley JA, Restrepo BI, Ronacher K, Kapur A, Bremer AA, Schlesinger LS, Basaraba R, Kornfeld H, van Crevel R.

Chest. 2017 Jul;152(1):165-173. doi: 10.1016/j.chest.2017.04.155. Epub 2017 Apr 20. Review.

8.

An aerosol challenge model of tuberculosis in Mauritian cynomolgus macaques.

Sharpe SA, White AD, Sibley L, Gleeson F, Hall GA, Basaraba RJ, McIntyre A, Clark SO, Gooch K, Marsh PD, Williams A, Dennis MJ.

PLoS One. 2017 Mar 8;12(3):e0171906. doi: 10.1371/journal.pone.0171906. eCollection 2017.

9.

The Discovery of 2-Aminobenzimidazoles That Sensitize Mycobacterium smegmatis and M. tuberculosis to β-Lactam Antibiotics in a Pattern Distinct from β-Lactamase Inhibitors.

Nguyen TV, Blackledge MS, Lindsey EA, Minrovic BM, Ackart DF, Jeon AB, Obregón-Henao A, Melander RJ, Basaraba RJ, Melander C.

Angew Chem Int Ed Engl. 2017 Mar 27;56(14):3940-3944. doi: 10.1002/anie.201612006. Epub 2017 Mar 1.

PMID:
28247991
10.

A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment.

Podell BK, Ackart DF, Richardson MA, DiLisio JE, Pulford B, Basaraba RJ.

Dis Model Mech. 2017 Feb 1;10(2):151-162. doi: 10.1242/dmm.025593. Epub 2017 Jan 12.

11.

Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations.

Sharpe S, White A, Sarfas C, Sibley L, Gleeson F, McIntyre A, Basaraba R, Clark S, Hall G, Rayner E, Williams A, Marsh PD, Dennis M.

Tuberculosis (Edinb). 2016 Dec;101:174-190. doi: 10.1016/j.tube.2016.09.004. Epub 2016 Oct 8.

12.

Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.

Kiran D, Podell BK, Chambers M, Basaraba RJ.

Semin Immunopathol. 2016 Mar;38(2):167-83. doi: 10.1007/s00281-015-0537-x. Epub 2015 Oct 28. Review.

13.

Second generation 2-aminoimidazole based advanced glycation end product inhibitors and breakers.

Furlani RE, Richardson MA, Podell BK, Ackart DF, Haugen JD, Melander RJ, Basaraba RJ, Melander C.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4820-4823. doi: 10.1016/j.bmcl.2015.06.080. Epub 2015 Jun 29.

14.

Inhibition and breaking of advanced glycation end-products (AGEs) with bis-2-aminoimidazole derivatives.

Richardson MA, Furlani RE, Podell BK, Ackart DF, Haugen JD, Melander RJ, Melander C, Basaraba RJ.

Tetrahedron Lett. 2015;56(23):3406-3409.

15.

Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis.

Irwin SM, Driver E, Lyon E, Schrupp C, Ryan G, Gonzalez-Juarrero M, Basaraba RJ, Nuermberger EL, Lenaerts AJ.

Dis Model Mech. 2015 Jun;8(6):591-602. doi: 10.1242/dmm.019570. Epub 2015 Mar 30.

16.

Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis.

Bai X, Shang S, Henao-Tamayo M, Basaraba RJ, Ovrutsky AR, Matsuda JL, Takeda K, Chan MM, Dakhama A, Kinney WH, Trostel J, Bai A, Honda JR, Achcar R, Hartney J, Joosten LA, Kim SH, Orme I, Dinarello CA, Ordway DJ, Chan ED.

Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5111-6. doi: 10.1073/pnas.1424302112. Epub 2015 Mar 27.

17.

Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion.

Schiebler M, Brown K, Hegyi K, Newton SM, Renna M, Hepburn L, Klapholz C, Coulter S, Obregón-Henao A, Henao Tamayo M, Basaraba R, Kampmann B, Henry KM, Burgon J, Renshaw SA, Fleming A, Kay RR, Anderson KE, Hawkins PT, Ordway DJ, Rubinsztein DC, Floto RA.

EMBO Mol Med. 2015 Feb;7(2):127-39. doi: 10.15252/emmm.201404137.

18.

The formation of the granuloma in tuberculosis infection.

Orme IM, Basaraba RJ.

Semin Immunol. 2014 Dec;26(6):601-9. doi: 10.1016/j.smim.2014.09.009. Epub 2014 Oct 22. Review.

PMID:
25453231
19.

Microhemorrhage is an early event in the pulmonary fibrotic disease of PECAM-1 deficient FVB/n mice.

Lishnevsky M, Young LC, Woods SJ, Groshong SD, Basaraba RJ, Gilchrist JM, Higgins DM, Gonzalez-Juarrero M, Bass TA, Muller WA, Schenkel AR.

Exp Mol Pathol. 2014 Aug;97(1):128-36. doi: 10.1016/j.yexmp.2014.06.008. Epub 2014 Jun 24.

20.

Mycobacterium tuberculosis Lsr2 is a global transcriptional regulator required for adaptation to changing oxygen levels and virulence.

Bartek IL, Woolhiser LK, Baughn AD, Basaraba RJ, Jacobs WR Jr, Lenaerts AJ, Voskuil MI.

MBio. 2014 Jun 3;5(3):e01106-14. doi: 10.1128/mBio.01106-14.

Supplemental Content

Loading ...
Support Center